- Conditions
- Bladder Cancer, Non-muscle Invasive Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- Photocure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Iowa City, Iowa • Ann Arbor, Michigan + 2 more
Location Directory
Clinical trials in Nashville, Tennessee
This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10880
Shown on this page
12
Current sort
Recently updated
Location scope
Nashville, TN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 637–648 of 10,880 matching trials in Nashville, TN.
Live ClinicalTrials.gov results.
Institutions in Nashville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
- Interventions
- JANX007, Darolutamide
- Biological · Drug
- Lead sponsor
- Janux Therapeutics
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Cancer
- Interventions
- Not listed
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Fort Lauderdale, Florida • Columbus, Ohio • Nashville, Tennessee
- Conditions
- Congenital Diaphragmatic Hernia
- Interventions
- Inhaled Nitric Oxide (iNO) use, De-implementation of Inhaled Nitric Oxide (iNO) use
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 0 Months to 1 Month
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 16 more
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
- Interventions
- STK-012, pembrolizumab KEYTRUDA®, pemetrexed, carboplatin
- Drug
- Lead sponsor
- Synthekine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Beverly Hills, California • Fullerton, California + 28 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 77
- States / cities
- Tucson, Arizona • Springdale, Arkansas • Anaheim, California + 69 more
- Conditions
- Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Primary Myelofibrosis (PMF)
- Interventions
- PRT12396
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Sacramento, California • Denver, Colorado + 7 more
- Conditions
- Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer, Non-small Cell Lung Cancer, Urothelial Carcinoma
- Interventions
- GEN1107
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Sarasota, Florida • Boston, Massachusetts + 3 more
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
- Interventions
- GVV858, Fulvestrant, Letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Nashville, Tennessee • San Antonio, Texas
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
- Interventions
- Rapcabtagene autoleucel single agent, Ibrutinib
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Stanford, California • Tampa, Florida + 9 more
- Conditions
- Aortic Valve Regurgitation, Aortic Valve Disease Mixed
- Interventions
- J-Valve Transfemoral (TF) System
- Device
- Lead sponsor
- JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more
- Conditions
- Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal, C9orf72
- Interventions
- PBFT02
- Drug
- Lead sponsor
- Passage Bio, Inc.
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more